Overview of the new oral anticoagulants: opportunities and challenges

Arteriosclerosis, Thrombosis, and Vascular Biology
Calvin H YehJeffrey I Weitz

Abstract

The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for many indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxaban, which inhibit factor Xa. All 4 agents are licensed in the United States for stroke prevention in atrial fibrillation and for treatment of venous thromboembolism and rivaroxaban and apixaban are approved for thromboprophylaxis after elective hip or knee arthroplasty. The NOACs are at least as effective as warfarin, but are not only more convenient to administer because they can be given in fixed doses without routine coagulation monitoring but also are safer because they are associated with less intracranial bleeding. As part of a theme series on the NOACs, this article (1) compares the pharmacological profiles of the NOACs with that of warfarin, (2) identifies the doses of the NOACs for each approved indication, (3) provides an overview of the completed phase III trials with the NOACs, (4) briefly discusses the ongoing studies with the NOACs for new indications, (5) reviews the emerging real-world data with the NOACs, and (6) highlights the potential opportunities for the NOACs and identifies the remaining challenges.

References

Dec 24, 2010·The New England Journal of Medicine·Michael Rud LassenUNKNOWN ADVANCE-3 Investigators
Feb 12, 2011·The New England Journal of Medicine·Stuart J ConnollyUNKNOWN AVERROES Steering Committee and Investigators
Mar 2, 2011·Journal of Thrombosis and Thrombolysis·Alexander Thomas CohenVictor Tapson
Jul 26, 2011·The New England Journal of Medicine·John H AlexanderUNKNOWN APPRAISE-2 Investigators
Nov 15, 2011·The New England Journal of Medicine·Samuel Z GoldhaberUNKNOWN ADOPT Trial Investigators
Nov 15, 2011·The New England Journal of Medicine·Jessica L MegaUNKNOWN ATLAS ACS 2–TIMI 51 Investigators
Dec 12, 2012·The New England Journal of Medicine·Giancarlo AgnelliUNKNOWN AMPLIFY-EXT Investigators
Feb 22, 2013·The New England Journal of Medicine·Sam SchulmanUNKNOWN RE-SONATE Trial Investigators
Mar 15, 2013·The New England Journal of Medicine·Mary Ross SouthworthEllis F Unger
Apr 9, 2013·Journal of the American College of Cardiology·Torben Bjerregaard LarsenGregory Y H Lip
Sep 3, 2013·The New England Journal of Medicine·John W EikelboomUNKNOWN RE-ALIGN Investigators
May 31, 2014·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Gabriel V FontaineR Scott Evans
Aug 12, 2014·The American Journal of Medicine·Mary S Vaughan SarrazinPeter Cram
Aug 27, 2014·Circulation·John SimesUNKNOWN INSPIRE Study Investigators (International Collaboration of Aspirin Trials for Recurrent Venous Thromboembolism)
Dec 20, 2014·Journal of Thrombosis and Haemostasis : JTH·N C ChanJ W Eikelboom
Jan 24, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Edward T Carreras, Jessica L Mega
Feb 27, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Farzana Bacchus, Sam Schulman
Mar 15, 2015·Arteriosclerosis, Thrombosis, and Vascular Biology·Cory Messerschmidt, Richard J Friedman

❮ Previous
Next ❯

Citations

Oct 17, 2015·Expert Review of Cardiovascular Therapy·Noel C ChanJohn W Eikelboom
Jul 21, 2015·Expert Review of Cardiovascular Therapy·Jack Ansell
Oct 9, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Julian FriebelUrsula Rauch
Mar 28, 2016·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Gerard ChaayaAnalia Castiglioni
Jun 4, 2016·Air Medical Journal·Richard L Summers, Sarah A Sterling
Apr 16, 2016·International Journal of Cardiology·Ramyashree TummalaRaktim Kumar Ghosh
Jun 14, 2015·Current Problems in Surgery·Dawn M ColemanPeter K Henke
Jul 2, 2016·Pharmacognosy Research·Raju DashMir Muhammad Nasir Uddin
May 15, 2016·Clinical Pharmacology and Therapeutics·Steven R Lentz
Jul 28, 2016·Nature Medicine·Nabil K ThaljiRodney M Camire
Aug 26, 2016·Science Translational Medicine·Tovo DavidShaun R Coughlin
Aug 30, 2016·The American Journal of Medicine·Menno V Huisman, John Fanikos
Sep 18, 2016·Hematology/oncology Clinics of North America·Allison P Wheeler, David Gailani
Oct 5, 2016·The American Journal of Emergency Medicine·Menno V Huisman, John Fanikos
Oct 19, 2016·Scientific Reports·Fumihiro SanadaRyuichi Morishita
Jun 2, 2017·JCI Insight·Yunmei WangDaniel I Simon
Feb 27, 2016·The Annals of Pharmacotherapy·Shannon W FinksPaul P Dobesh
Jul 19, 2017·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Davide ImbertiUNKNOWN eXperience VTE Italian Group
Feb 7, 2018·Journal of Stroke·Woohyeun Kim, Eung Ju Kim
May 14, 2016·Arteriosclerosis, Thrombosis, and Vascular Biology·David Gailani, Andras Gruber
Dec 26, 2018·Arteriosclerosis, Thrombosis, and Vascular Biology·Jens J PosmaNigel Mackman
May 6, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Maureen A SmytheJohn Fanikos
May 6, 2016·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Michael P Gulseth
Dec 23, 2015·World Journal of Hepatology·Massimo PrimignaniVincenzo La Mura
Jun 3, 2017·Journal of Thrombosis and Haemostasis : JTH·J-D StudtM Nagler
Aug 2, 2017·Pharmacoepidemiology and Drug Safety·Francesca Valent
Feb 6, 2020·Journal of Cardiovascular Pharmacology·Jesus Hernandez-JuarezAbraham Majluf-Cruz
Jul 12, 2017·Current Opinion in Hematology·Nabil K Thalji, Rodney M Camire
Aug 26, 2015·ChemMedChem·Daniela HäußlerMichael Gütschow
Apr 2, 2017·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Janaki Krishnamoorthy IyerR Manjunatha Kini
May 20, 2017·Scientific Reports·David A DonkorWilliam P Sheffield
May 16, 2019·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Fakiha SiddiquiJawed Fareed
Nov 18, 2017·European Journal of Clinical Pharmacology·Anne Katrine EekAnne Gerd Granas
May 21, 2020·Minerva cardioangiologica·Silvio RomanoLuigi Sciarra
Jul 10, 2017·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Ipek CelikyurtBeat Schaer
Jul 27, 2018·Research and Practice in Thrombosis and Haemostasis·Lana A CastellucciGrégoire Le Gal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.